RenovoRx launches post-marketing study to advance real-world use of RenovoCath Device

Real-world use of RenovoCath device launches: ©Juan Gartner - stock.adobe.com

RenovoRx Inc. (Nasdaq: RNXT) announced the launch of its PanTheR Post-Marketing Registry Study, a multi-center, observational study aimed at evaluating the long-term safety and real-world effectiveness of the company’s RenovoCath drug-delivery device in treating solid tumors.

The first site to initiate patient enrollment is the University of Vermont Cancer Center, with Conor O’Neill, assistant professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, serving as principal investigator. Additional clinical sites are expected to begin enrolling patients later this year, with the company projecting enrollment to start before the end of September 2025.

“PanTheR marks a significant step forward in our commitment to better understand and demonstrate the long-term safety and therapeutic potential of our RenovoCath device,” said Leesa Gentry, chief clinical officer of RenovoRx. “By collaborating with leading cancer centers across the U.S., this is a low-cost study that will yield valuable data. By gathering real-world data across diverse cancer types and clinical environments, PanTheR aims to advance innovation and inform evidence-based treatment strategies, which will ultimately enhance care and potentially improve outcomes for future patients facing solid tumors.”

PanTheR will collect observational, real-world data from patients diagnosed with solid tumors who are treated using RenovoCath. According to the company, the study is designed to capture safety and performance data across a broader range of tumor types and clinical settings and may inform future clinical trial design.

“We are very pleased that the UVM Cancer Center has been initiated to begin enrollment in the PanTheR study,” Gentry added. “The UVM Cancer Center offers leading-edge care, provided by highly skilled oncologists priding themselves on using the latest research and education for informed care. We believe our study will be an excellent fit within University of Vermont’s oncology program.”

O’Neill said the study aligns with the center’s mission to expand treatment innovation. “We are proud to be part of this important study that holds the potential to transform the way we treat solid tumors,” he said. “I believe the RenovoCath device offers a novel approach for drug delivery, which may have the potential to improve patient outcomes. This study emphasizes our strong commitment to continually advance treatment options offered to our patients by offering access to the latest innovations that have the potential to transform the treatment paradigm for solid tumors.”

Targeted drug delivery and the future of solid tumor treatment

The development and deployment of targeted drug delivery systems for solid tumors represent a fast-growing area in oncology, with the goal of increasing therapeutic efficacy while reducing systemic toxicity. These delivery methods aim to bring chemotherapy or other drugs directly to the tumor site, sparing healthy tissue and potentially improving quality of life and outcomes for patients.

Recent advances have leveraged catheter-based systems, microfluidic devices, and biodegradable implants to deliver anti-cancer agents precisely where they are needed. These systems can be customized to specific anatomical locations or tumor types, making them adaptable across a wide variety of cancers, including pancreatic, liver, and colorectal tumors.

A growing body of research supports the clinical utility of these approaches, especially in cancers that are difficult to treat with traditional systemic chemotherapy. By concentrating drugs in the tumor environment, targeted delivery can help overcome challenges such as drug resistance and poor vascularization that often limit treatment success.

In addition to hardware innovations, advancements in imaging and diagnostic integration are enhancing the precision of targeted therapy. Physicians can now visualize tumor response in real time and adjust treatment protocols accordingly. Furthermore, registry studies like PanTheR are critical to capturing post-approval, real-world data, offering a broader understanding of how these devices perform across diverse populations and treatment settings.

As the oncology field continues to shift toward personalized and minimally invasive approaches, targeted drug delivery systems are expected to play a central role in shaping next-generation cancer care.